Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · Real-Time Price · USD
1.210
0.00 (0.00%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Ikena Oncology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Ikena Oncology stock have an average target of 3.00, with a low estimate of 2.00 and a high estimate of 4.00. The average target predicts an increase of 147.93% from the current stock price of 1.21.
Analyst Consensus: Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
The average analyst rating for Ikena Oncology stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +230.58% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +230.58% | Aug 12, 2024 |
| Wedbush | Wedbush | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +65.29% | May 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $4 | Strong Buy | Maintains | $11 → $4 | +230.58% | May 29, 2024 |
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +561.16% | May 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.83
from -1.02
EPS Next Year
-0.83
from -0.83
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.64 | -0.51 | -0.49 |
| Avg | -0.83 | -0.83 | -0.98 |
| Low | -1.00 | -1.11 | -1.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.